Biotech & Pharma Updates | February 17 - 18, 2026
🧬 J&J to build $1B cell therapy plant in Pennsylvania, creating 500 jobs as part of their $55B US investment plan, Danaher buys patient monitoring specialist Masimo in $9.9B deal to strengthen diagnostics portfolio, Korsana Biosciences launches with $150M series A to advance next-generation anti-amyloid Alzheimer's antibody KRSA-028, Eli Lilly's Zepbound (tirzepatide) plus Taltz combination shows Ph3 efficacy in moderate-to-severe plaque psoriasis, Merck & Co. + Mayo Clinic partner on AI drug discovery using multimodal patient data platform, Novartis + Unnatural Products partner on cardiovascular macrocyclic peptides for $100M upfront and $1.7B in biobucks, EIR Biopharma targets $17M IPO - preclinical eye disease drug development
